Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
44 articles
Newest firstMOTIVATION: Opioid use disorder (OUD) often emerges following prescription opioid exposure and follows a dynamic clinical course characterized by onset, remission, and relapse. Large-scale cohorts linking electronic health records (EHR) with rich longitudinal survey data, such as the All of Us Research Program, enable computational modeling of stage-specific risk and provide an opportunity to connect predictive fa…
Open article record in new tab ↗Background Opioid use disorder (OUD), particularly injection drug use (IDU), is on the rise and is associated with complications such as blood-borne infections, overdosing, and seizures, among others. Understanding factors distinguishing non-injecting opioid users (NIOU) and IDUs is essential for the development of effective prevention and management strategies. This study aimed to compare sociodemographic, clinic…
Open article record in new tab ↗Background Cannabinoids are increasingly discussed as adjuncts in addiction treatment, yet whether they improve clinically meaningful substance use disorder (SUD) outcomes beyond short-term symptom relief is unresolved. We determined whether cannabinoid exposure confers directional efficacy across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders, distinguishing symptomatic targets from sustaine…
Open article record in new tab ↗Background Substance use disorders (SUDs) remain a major source of preventable morbidity and mortality in the United States. This study described trends in the burden of SUDs from 1990 to 2019 by substance, sex, and age, and examined whether state-level policy environments and behavioral health budgets differed across states with the highest and lowest SUD-related disability-adjusted life years (DALYs). Methods We…
Non-medical use of cannabis (NmC) and/or opioids (NmO) can lead to adverse health effects (AHEs), yet the proportion of these harms attributable to adverse childhood experiences (ACEs) remains unclear. This study estimated the contribution of ACEs to AHEs from NmC and/or NmO among adults aged ≥18 years using 2019-2020 Behavioral Risk Factor Surveillance System data from Arizona and Massachusetts. We conducted a re…
Long-acting injectable (LAI) formulations of pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) offer promising new approaches for addressing the intersecting challenges of HIV and opioid use disorder (OUD) in carceral settings. However, successful implementation requires understanding the perspectives of key carceral and community stakeholders. This qualitative study involved 17 semi-s…
Open article record in new tab ↗Background Drug use disorders (DUDs), a significant public health issue worldwide, encompass disorders related to sedatives, cannabis, opioids, heroin, hallucinogens, club drugs, and inhalants. This study examines the changes in the global burden of DUDs from 1990 to 2021, aiming to provide a scientific foundation for strategies to mitigate the harms associated with substance abuse. Methods The study utilized Glob…
Open article record in new tab ↗Cannabidiol (CBD) has emerged as a potential treatment option for various psychiatric disorders, including substance use disorders. This systematic review is aimed at reviewing the evidence regarding the safety and efficacy of CBD as a therapeutic option in opioid use disorder (OUD) treatment in clinical and preclinical studies. We searched MEDLINE, Embase, PsycINFO, Scopus, Web of Science, CDSR and CENTRAL up to…
Background The objective of this qualitative study was to better understand the experiences of individuals living with opioid use disorder (OUD) and chronic pain using medical cannabis (MC) for 12 months. Methods Perspectives were captured via 10 key informant interviews conducted after 12 months of treatment with MC RESULTS: Key themes identified regarding the reasons for initially pursuing MC included: (1) canna…
Background Medical cannabis (MC) is approved for the treatment of opioid use disorder (OUD) in Pennsylvania, but little is known about how MC impacts illicit opioid use or the clinical and psychosocial factors including pain severity levels that can precede illicit opioid use. This observational study examined the extent to which changes in rates of illicit opioid use and in pain and psychosocial functioning were…
Open article record in new tab ↗Background/Objectives: Adolescents and young adults (AYAs) with opioid use disorder (OUD) frequently have co-occurring psychiatric conditions and substance use disorders (SUDs). This study evaluated the association of psychiatric comorbidities and other SUDs with treatment retention and urine drug test (UDT) results in AYAs with OUD. Methods: This retrospective cohort study included AYAs enrolled in the Substance…
Abstract The endocannabinoid (eCB) system has been proposed as a potential target for developing new medications for opioid use disorder (OUD). However, the status of the eCB system, specifically brain cannabinoid receptor type 1 (CB1R) in OUD, is unknown. In this study, CB1R availability was measured in males with OUD on stable opioid agonist treatment (OAT) (n = 10) versus healthy controls (HC) (n = 18), using H…
Background Opioid use disorder often co-occurs with other mental health and substance use disorders. Identifying clusters of individuals receiving treatment for opioid use disorder based on co-diagnosed conditions, healthcare plans, and service utilization over a seven-year treatment period provides insight into service needs. Objectives included [1] characterizing the sample [2], examining subtypes of the sample…
This narrative review explores current insights into the potential use of medicinal cannabis-related products as an emerging therapy for opioid use disorder in the landscape of increasing knowledge about medicinal cannabis-based products, commercialisation and global legalisation. Preclinical studies have provided preliminary insight into the putative neurobiological mechanisms that underpin the potential for medi…
Open article record in new tab ↗Background Individuals with opioid use disorder (OUD) often have concurrent use of non-opioid substances. When patients enter opioid maintenance treatment (OMT), less is known about outcomes regarding the use of other types of drugs. Here we aimed to investigate changes in substance use among patients entering outpatient OMT, from treatment initiation to 1-year follow-up. Methods We used data from the prospective…
Open article record in new tab ↗Background Cannabidiol (CBD) is a widely available cannabis product with many claims as to potential health benefits including alleviating symptoms related to opioid use disorder (OUD). However, little is known as to how individuals with OUD perceive CBD, to what extent they may already be using CBD, and for what purposes. Methods A survey was conducted among individuals receiving treatment for OUD at the Addictio…
Open article record in new tab ↗Background The lockdown measures during the SARS-CoV-2 pandemic could have influenced drug consumption patterns of persons with drug use disorder, especially due to a reduced availability of drugs, an increased consumption of sedating substances as a coping strategy, or a shift to novel psychotropic substances (NPS) associated with an increased drug buying in the internet. In this study, the consumption patterns o…
ContextOpioid use disorder (OUD) poses significant public health problems that have increased dramatically, resulting in high rates of morbidity and mortality.ObjectivesTo minimize the risk of an opioid epidemic in Israel and be prepared, we evaluated physicians’ objective knowledge, level of stigma, and approach to prescribing opioids, risk factors, and identification of patients with substance use disorder (SUD)…
Open article record in new tab ↗Co-occurring cannabis use is common among those with opioid use disorder (OUD), but the extent to which it is harmful may be due to its preparation and concentration of various cannabinoids. The current study aimed to examine the prevalence of, and long-term associations with, the use of varying cannabis products among a naturalistic longitudinal cohort of people with heroin dependence. A total of 615 people, most…